Miromatrix Medical
Engaged in the development of fully biological human organs and organ-derived biological products.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $91.0m Valuation: $91.0m | Acquisition | |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (81 %) | (29 %) | 2784 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (3654 %) | (24599 %) | (50772 %) | (3137 %) |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1619 %) | (22157 %) | (44368 %) | (3142 %) |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 2507 % | 15648 % | 32512 % | 1920 % |
Source: Company filings or news article
Related Content
Miromatrix is a pioneering company focused on eliminating the organ transplant waiting list by bioengineering transplantable organs such as liver, kidney, and heart. The company operates in the healthcare and biotechnology markets, serving patients in need of organ transplants and medical institutions that perform these procedures. Miromatrix employs a proprietary perfusion recellularization process, which involves using decellularized organs as templates to support the growth and differentiation of cells into functional organs. This innovative approach aims to address the critical shortage of transplantable organs, offering a sustainable and scalable solution to a pressing medical issue.
Miromatrix's business model revolves around research and development, securing grants, and forming strategic partnerships with healthcare providers and research institutions. The company generates revenue through grants, such as the $1.9 million NIH grant for bioengineered liver development, and potential future sales of bioengineered organs. By focusing on cutting-edge biotechnology and regenerative medicine, Miromatrix is positioned to make a significant impact on the organ transplant landscape.
Keywords: bioengineering, transplantable organs, liver, kidney, heart, perfusion recellularization, healthcare, biotechnology, regenerative medicine, organ shortage, medical innovation.